The acute haemodynamic effects of 'pulsed' inhaled nitric oxide and iv epoprostenol in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005
The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003
Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Inhaled nitric oxide (NO) for vasoreactivity testing in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
Pulsed inhaled nitric oxide (iNO) improves exercise tolerance and shortness of breath (SOB) in severe COPD subjects with pulmonary hypertension (PH) Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018
Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006
Haemodynamic testing in primary pulmonary hypertension - effects of nitric oxide, iloprost and oxygen Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001
Effect of systemic and extra-fine particle inhaled corticosteroids on corrected alveolar nitric oxide (CANO) in COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Optimising inhaled corticosteroid (ICS) dose using exhaled nitric oxide (eNO) measurements Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002
Influence of inhaled nitric oxide on plasma endothelin-1 in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003
Benefit of inhaled corticosteroids (ICS) in asthmatic patients with bronchial hyperresponsiveness (BHR) to mannitol and low fractional exhaled nitric oxide (FeNO) levels Source: International Congress 2017 – Monitoring asthma control Year: 2017
Effect of inhaled steroids and long-acting β2 agonists on exhaled nitric oxide (eNO) in asthmatic children Source: Eur Respir J 2004; 24: Suppl. 48, 270s Year: 2004
Non-adherence to inhaled corticosteroid therapy as an explanation for persistently elevated exhaled nitric oxide levels in patients with asthma: Effect of directly observed therapy with inhaled corticosteroids (DOT-ICS) Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
The effect of switching cyclosporin A (CyA) to tacrolimus (FK) on exhaled nitric oxide (eNO) and pulmonary function in patients with chronic rejection after lung transplantation (LTx) Source: Eur Respir J 2002; 20: Suppl. 38, 564s Year: 2002
Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children Source: Eur Respir J 2002; 20: 630-634 Year: 2002
Acute vasoresponsiveness to inhaled nitric oxide in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008
Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes? Source: International Congress 2018 – Clinical and functional monitoring in airway disease Year: 2018